AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04967469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: end-stage renal failure patients who is hyperparathyroid with ESRD take calcidol preoperative Parathyroidectomy
Study NCT04967469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol 0.5 MCG Oral Capsule
Description: end-stage renal failure patients who is hyperparathyroid with ESRD take alfacalcidol preoperative Parathyroidectomy
Study NCT03513185 — intervention group
Intervention type: DRUG
Intervention: Deanxit, SSRI or SRNI
Description: After recruiting participants and collecting the baseline data, the SSS-CN, PHQ-15, PHQ-9 and GAD-7 questionnaires will be carried out. An independent diagnosis will be made by primary care physician using the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criterion standard. Deanxit, selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI) will be selectively prescribed according to the severity category assessed by physician. Two, 6,10 weeks after patients with correspondent medications, a face-to-face interview, telephone interview or mobile-apps survey will be underwent to follow-up using the SSS-CN, PHQ-15, PHQ-9 and GAD-7 checklists.
Study NCT01418222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: Intravenous repeating dose
Study NCT01418222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intravenous repeating dose
Study NCT01426568 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Convergent Therapy
Description: Cognitive Behavioural Therapy Relaxation Techniques Meditation Stress Management
Study NCT01026402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: Dose escalation phase: a single dose taken orally (solution or tablet) of AZD2014 on single dose day 1 (visit 2), followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or Single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal. Expansion phase: twice daily dosing from day 1 until discontinuation or withdrawal or a single dose taken orally of AZD2014 on single dose day 1 (visit 2), followed by a single dose on second single dose day 1 (visit 3) after a washout period (48 hours - 7 days) followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal.
Study NCT02241577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: Flap surgery around dental implant for scaling and disinfection of the titanium surface under local anesthesia
Study NCT02241577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment
Description: Non-surgical subgingival scaling and disinfection of the titanium surface of dental implant under local anesthesia
Study NCT00584753 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Positron emission tomography and computed tomography
Description: Positron emission tomography and computed tomography
Study NCT00584753 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Positron emission tomography and computed tomography
Description: Positron emission tomography and computed tomography
Study NCT01015573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic sensor system to measure the movements of finger tapping
Study NCT04123379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: q4w, dosed twice before surgery and three times following recovery from surgery by injection
Study NCT04123379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: 300mg oral twice a day for 28 days
Study NCT04123379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: 2400mg once by injection
Study NCT05679297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative sensory testing (QST)
Description: The QST is a standardized, internationally accepted test battery consisting of several well-established, non-invasive tests, measuring parameters, which reflect nearly all aspects of somatosensation.~1. Thermal detection threshold for the perception of cold, warm and paradoxical heat sensations~2. Thermal pain threshold~3. Mechanical detection thresholds for touch~4. Mechanical pain threshold for pinprick stimuli~5. Stimulus-response functions~6. Wind- up ratio: The wind- up ratio represents the quotient of the pain intensity evoked by 10 pin-prick stimuli and the pain intensity evoked by one single pin-prick stimulus~7. Vibration detection threshold~8. Pressure pain threshold
Study NCT05679297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: Functional and structural MRI data will be collected using a 3 Tesla Siemens Scanner with a multi-channel head coil.~For the resting state functional MRI the subjects will merely lie in the scanner for about 10 minutes.~A painful heat/cold stimulation will be performed to study the differences in pain processing between the three groups
Study NCT05679297 — intervention group
Intervention type: OTHER
Intervention: Clinical interview/exam
Description: The pain characteristics will be assessed through a standardized questionnaire. The german pain questionnaire is a validated questionnaire that assesses various dimensions of pain. Patients will also get a complete neurological examination by an experienced clinician.
Study NCT05679297 — intervention group
Intervention type: OTHER
Intervention: Follow-up interview
Description: Structured telephone interview with 3 Questionnaires~1. The german pain questionnaire~2. Questionnaire regarding clinical development since the last visit designed by the investigators~3. German translation of 12-item-allodynia symptom checklist (ASC-12)
Study NCT04261712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paltusotine
Description: Paltusotine, once daily by mouth
Study NCT01017120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Foam
Description: Tazarotene foam once a day application to the face
Study NCT01017120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam once a day application to the face
Study NCT01418222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: Intravenous repeating dose
Study NCT01418222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab [Avastin]
Description: Intravenous repeating dose
Study NCT01418222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Intravenous repeating dose
Study NCT01418222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: Intravenous repeating dose
Study NCT01418222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onartuzumab [MetMAb]
Description: Intravenous repeating dose
Study NCT03844516 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Peak oxygen uptake test with pacing
Description: Peak oxygen uptake test with paced heart rate
Study NCT03844516 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Peak oxygen uptake test without pacing
Description: Peak oxygen uptake test without paced heart rate
Study NCT02702258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MB-BP
Description: MB-BP (Mindfulness-Based Blood Pressure Reduction) customizes Mindfulness-Based Stress Reduction (MBSR) to participants with prehypertension/hypertension. MB-BP will consist of nine 2.5-hour weekly group sessions and an 7.5-hour one-day session. Some of the unique areas of MB-BP are education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of blood pressure determinants such as diet, physical activity, antihypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week.
Study NCT02338713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcichew D3
Description: Calcium 500 mg and vitamin D3 1000 IU chewable tablets
Study NCT02338713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noncarbonated Water
Description: Noncarbonated water 200 mL
Study NCT04173663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASSIST
Description: The ASSIST program is a 12-week advocacy training to educate parents of youth with autism about the adult service system (note that an optional 13th session on secondary transition planning can be offered if ASSIST is being delivered to families of youth who are in high school). It is a group training, comprised of didactic instruction, family-sharing activities, case studies, and group discussions. The ASSIST program for the proposed study will be directed at each site by an experienced Program Facilitator from the community with knowledge about group processes, person-centered planning, and adult service systems, who will be coached by a member of the study team. The ASSIST program will be delivered in full partnership with the local disability community. In most sessions, the Program Facilitator will be aided by community content experts who present the specifics of each topic.
Study NCT04173663 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ASSIST
Description: The ASSIST program is a 12-week advocacy training to educate parents of youth with autism about the adult service system (note that an optional 13th session on secondary transition planning can be offered if ASSIST is being delivered to families of youth who are in high school). It is a group training, comprised of didactic instruction, family-sharing activities, case studies, and group discussions. The ASSIST program for the proposed study will be directed at each site by an experienced Program Facilitator from the community with knowledge about group processes, person-centered planning, and adult service systems, who will be coached by a member of the study team. The ASSIST program will be delivered in full partnership with the local disability community. In most sessions, the Program Facilitator will be aided by community content experts who present the specifics of each topic.
Study NCT01565018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine PR 2.1.4
Description: Treatment B: Rotigotine transdermal patch (2 mg/24 h \[10 cm\^2\]). Reference; drug product PR 2.1.4. Single application of 1 patch for 24 hours.
Study NCT00401583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034 (pazopanib)
Description: Pazopanib will be given as monohydrochloride, 100 and 500 mg tablets.
Study NCT01565018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine PR 2.2.1
Description: Treatment A: Rotigotine transdermal patch (2 mg/24 h \[10 cm\^2\]). Test; drug product PR 2.2.1. Single application of 1 patch for 24 hours.
Study NCT00333788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CDP870)
Description: 400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks
Study NCT00401583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probe drugs
Description: probe drugs will be oral midazolam (3 mg), warfarin (10 mg), omeprazole (40 mg), caffeine (200 mg), and dextromethorphan (30 mg).
Study NCT00593112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Description: Concerta is given in capsule form with a minimum dose of 18 mg/day and a max of 126 mg/day. Subjects take Concerta once per day for 6 weeks.
Study NCT01813864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CASPAR/Treatment Planning
Description: All counselors in the study will receive additional training in treatment planning and the CASPAR Resource Guide software to easily identify and link patients to services not available at substance abuse treatment centers such as General Educational Development (GED) training, dental clinics, job training, etc.
Study NCT03708133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (Lampit, BAYA2502)_Test
Description: Orally intake of 1 \*120mg new formulation tablet as test treatment
Study NCT03708133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (Lampit, BAYA2502)_Reference
Description: Orally intake of 1 \*120mg current clinical formulation tablet as reference treatment
Study NCT01927016 — intervention group
Intervention type: PROCEDURE
Intervention: Esophagectomy
Description: Esophagectomy for esophageal cancer whatever can be the surgical approach (with or without thoracotomy, minimally invasive or not)
Study NCT03967262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention
Description: The objective of motivational intervention is to make the patient aware of the relationship between the consumption of alcohol and other drugs and the accident, and induce them to carry out a change in habits.
Study NCT01049581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aquatic therapy
Description: two hours per week, one hour per time, total 12 weeks
Study NCT04367142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 RT-PCR
Description: Nasopharyngeal swabs for COVID-19 RT-PCR
Study NCT04367142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biosensor
Description: Portable and Connected Biosensor viral
Study NCT01261767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IL-20
Description: Anti-IL-20 in 100mg/vial for subcutaneous (under the skin) injection
Study NCT03092960 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal intensity intervention
Description: The minimal intensity intervention control includes the Group Lifestyle Balance (GLB) videos (DVD or online), standardized messages, and access to a lifestyle coach if initiated by the participant.
Study NCT03092960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOMBRE
Description: HOMBRE is a Group Lifestyle Balance (GLB)-based intervention tailored for men and available in 3 delivery modalities (coach-facilitated individual approach, coach-led online virtual groups, and coach-led in-person groups). A lifestyle coach will support men in making an informed choice of modality and will provide ongoing individualized feedback. All delivery modalities provide the same evidence-based curriculum and include self-monitoring and individualized feedback from the lifestyle coach.
Study NCT00252928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium dichloroisocyanurate (NaDCC) tablets
Description: Intervention arm receives NaDCC tablets to use for to disinfect their household water for use for 20L of water. Ideally, disinfection occurs every day.
Study NCT00252928 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01406860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droperidol
Description: Droperidol 1.25 mg IV x 1, may repeat 0.625 mg if needed at 60 minutes
Study NCT01406860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide + diphenhydramine
Description: Metoclopramide 20 mg IV infusion q30 minutes as needed with a maximum of 4 doses + Diphenhydramine 25 mg IV injection x 1 given with the first dose of metoclopramide IV infusion and repeated x 1 given with the third metoclopramide IV infusion.
Study NCT02391285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dynamometer (Auckland vaginal elastometer)
Description: The elastometer is a modified vaginal speculum which captures pelvic muscle tone over 3 minutes and records this on an attached computer. In addition to the elastometer test, there are three further related tests, which patients would be suitable to participate in.~I. a questionnaire to fill in so as to obtain some feedback from patients regarding what they thought of the test and the device.~II. The investigators would like to repeat the elastometer measurement within a week of the first test to determine the reliability and accuracy of repeating the measurement after a few days.~III. The investigator would like to request that the patient have an MRI scan of the pelvic muscles to check whether the elastometer can pick up functional muscle weakness that would not otherwise be recognised except by performing an MRI scan. The investigators will therefore compare elastometer readings to the MRI scan findings.
Study NCT01940653 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Progesterone
Description: Procedures Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B. All patients with an endometrium less than 7 mm on day 13 of estrogen stimulation, are excluded.~Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 3 days of micronized progesterone vaginally. On the 5th (group A) or 3rd (group B) day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
Study NCT01940653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Procedures Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B. All patients with an endometrium less than 7 mm on day 13 of estrogen stimulation, are excluded.~Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 3 days of micronized progesterone vaginally. On the 5th (group A) or 3rd (group B) day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
Study NCT03565770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individual coaching
Description: coaching on the phone or with messages on line twice a month in order to help patients to adjust their insulin doses and fill in their self-assessment test.
Study NCT03565770 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard care
Description: completion of the self-assessment test at inclusion, at M6 and M12 for all study participants
Study NCT03565770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: completion of the self-assessment test at inclusion, at M6 and M12 for all study participants
Study NCT01286974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]linifanib
Description: \[14C\]linifanib, single administration, oral liquid
Study NCT01286974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869, linifanib
Description: linifanib once a day (QD), oral tablet
Study NCT03113760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadekinig alfa
Description: Tadekinig alfa is a soluble glycoprotein of 164 amino acids produced from Chinese Hamster Ovary cell line. Tadekinig alfa is supplied as a colorless to slightly yellow, sterile solution for injection in glass vials containing sodium chloride, and 0.02M sodium phosphate buffer as excipients. It is available in a concentration of 20mg/0.5mL.
Study NCT03113760 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: To ensure that the treatment remains blinded for the entire study period, the placebo solutions will be supplied in identical vials and similar labelling as the active drug and will be indistinguishable in terms of their texture, color, and smell.
Study NCT01284777 — intervention group
Intervention type: GENETIC
Intervention: blood sample, thoracocentesis
Description: 20ml of blood only one thoracocentesis (the same that one for diagnostic)
Study NCT00389974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO
Study NCT00697021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG
Description: Non- responders to Aspirin or Plavix shown on TEG analysis will be treated by doubling of Aspirin (200mg) and/or Plavix (150mg) dosage
Study NCT00697021 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 100mg and Plavix 75mg
Description: Responders to standard dual antiplatelet therapy as observed by TEG analysis will continue standard doses of Aspirin and Plavix
Study NCT02451904 — intervention group
Intervention type: OTHER
Intervention: Observation
Study NCT04716140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Debridement of the MTP1 cartillage lesion and microfracture
Description: Patients with a MTP1 cartillage lesion > grade I (based on based on the ICRS scale and an MS HoloLens measurement) randomised in the treatment group will be treated with debridement and microfracture
Study NCT04421378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral
Study NCT04421378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide (TMZ)
Description: Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral